TAK-164

N/A

Report date: 2024/02/05 13:55:33

Base Information

Drug NameTAK-164
Drug Alias NameTAK164TAK-164
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Ala-Ala dipeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DGN549 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAlkylating agentsDNA cross linking agentsAnti-Heat-stable enterotoxin receptor
TargetsDNAHeat-stable enterotoxin receptor
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColonic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunogen IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsStomach NeoplasmsColonic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A